{"id":"novartis-investigational-h5n1-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The H5N1 vaccine contains inactivated or recombinant viral antigens that train the adaptive immune system to recognize and respond to H5N1 avian influenza. Upon exposure to the actual virus, the pre-existing immune memory enables rapid production of neutralizing antibodies and T-cell responses to prevent infection or reduce disease severity.","oneSentence":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against H5N1 influenza virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:26.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of H5N1 avian influenza infection in at-risk populations"}]},"trialDetails":[{"nctId":"NCT02091908","phase":"PHASE3","title":"Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-04","conditions":"Influenza, Human","enrollment":540},{"nctId":"NCT02107807","phase":"PHASE3","title":"Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-04","conditions":"Influenza, Human, Flu, Human, Flu, Avian","enrollment":539}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Novartis Investigational H5N1 vaccine","genericName":"Novartis Investigational H5N1 vaccine","companyName":"Seqirus","companyId":"seqirus","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against H5N1 influenza virus. Used for Prevention of H5N1 avian influenza infection in at-risk populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}